Related references
Note: Only part of the references are listed.Effect of HER2 on prognosis and benefit from peri-operative chemotherapy in early oesophago-gastric adenocarcinoma in the MAGIC trial
A. F. C. Okines et al.
ANNALS OF ONCOLOGY (2013)
Her2/neu testing in gastric cancer: evaluating the risk of sampling errors
V. S. Warneke et al.
ANNALS OF ONCOLOGY (2013)
Current approaches and future directions in the treatment of HER2-positive breast cancer
Sara A. Hurvitz et al.
CANCER TREATMENT REVIEWS (2013)
Clinicopathologic features and treatment outcomes of patients with human epidermal growth factor receptor 2-positive adenocarcinoma of the esophagus and gastroesophageal junction
B. E. Phillips et al.
DISEASES OF THE ESOPHAGUS (2013)
HER2 expression and its clinicopathological features in resectable gastric cancer
Yoshiki Kataoka et al.
GASTRIC CANCER (2013)
Prognostic Implications of the Seventh Edition of the International Union Against Cancer Classification for Patients With Gastric Cancer: The Western Experience of Patients Treated in a Single-Center European Institution
Daniel Reim et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Cancer Statistics, 2012
Rebecca Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2012)
Intratumoral Heterogeneity Determines Discordant Results of Diagnostic Tests for Human Epidermal Growth Factor Receptor (HER) 2 in Gastric Cancer Specimens
Jiyuan Yang et al.
CELL BIOCHEMISTRY AND BIOPHYSICS (2012)
Impact of Expression of Human Epidermal Growth Factor Receptors EGFR and ERBB2 on Survival in Stage II/III Gastric Cancer
Masanori Terashima et al.
CLINICAL CANCER RESEARCH (2012)
Phase III Trial Comparing Capecitabine Plus Cisplatin Versus Capecitabine Plus Cisplatin With Concurrent Capecitabine Radiotherapy in Completely Resected Gastric Cancer With D2 Lymph Node Dissection: The ARTIST Trial
Jeeyun Lee et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Updated Analysis of SWOG-Directed Intergroup Study 0116: A Phase III Trial of Adjuvant Radiochemotherapy Versus Observation After Curative Gastric Cancer Resection
Stephen R. Smalley et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial
Yung-Jue Bang et al.
LANCET (2012)
Preoperative and Postoperative Chemotherapy for Gastric Cancer
Vikram K. Jain et al.
SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA (2012)
Alterations in the human epidermal growth factor receptor 2-phosphatidylinositol 3-kinase-v-Akt pathway in gastric cancer
Yasutaka Sukawa et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2012)
Prognosis significance of HER-2/neu overexpression/amplification in Chinese patients with curatively resected gastric cancer after the ToGA clinical trial
Fei Zhou et al.
WORLD JOURNAL OF SURGICAL ONCOLOGY (2012)
HER2 Testing in Gastric Cancer
Luca Albarello et al.
ADVANCES IN ANATOMIC PATHOLOGY (2011)
Global Cancer Statistics
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2011)
Perioperative Chemotherapy Compared With Surgery Alone for Resectable Gastroesophageal Adenocarcinoma: An FNCLCC and FFCD Multicenter Phase III Trial
Marc Ychou et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Gastric Adenocarcinoma Surgery and Adjuvant Therapy
Sameer H. Patel et al.
SURGICAL CLINICS OF NORTH AMERICA (2011)
Trastuzumab in gastric cancer
Alicia F. C. Okines et al.
EUROPEAN JOURNAL OF CANCER (2010)
A study of HER2 gene amplification and protein expression in gastric cancer
Benedict Yan et al.
JOURNAL OF CLINICAL PATHOLOGY (2010)
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
Yung-Jue Bang et al.
LANCET (2010)
HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target
C. Gravalos et al.
ANNALS OF ONCOLOGY (2008)
Signal transduction proteins in tumors from Puerto Rican and Caucasian gastric adenocarcinoma patients:: Expression differences with potential for specific targeted therapies
Jose Cangiano et al.
DIGESTIVE DISEASES AND SCIENCES (2008)
Why does Japan have a high incidence of gastric cancer? Comparison of gastritis between UK and Japanese patients
G. M. Naylor et al.
GUT (2006)
HER-2/neu amplification is an independent prognostic factor in gastric cancer
Dong Il Park et al.
DIGESTIVE DISEASES AND SCIENCES (2006)
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer
David Cunningham et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Share Paper
